Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471841) titled 'Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax' on March 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Timothy Pardee
Condition:
IDH1 Mutation
Relapsed / Refractory AML
Intervention:
Drug: Olutasidenib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 2026
Target Sample Size: 25
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07471841
Published by ...